Introduction
Multiple myeloma (MM) is a B cell neoplasia characterized by the accumulation of clonal malignant plasma cells in the bone marrow. In the majority of patients, malignant plasma cells require mediators delivered by the tumor environment to survive and proliferate. Interleukin-6 (IL-6) is one of these mediators produced in the bone marrow environment 1, 2 . However, IL-6 alone can support the growth of myeloma cells in vitro only in patients with extramedullary proliferation 3 . In patients with intramedullary MM, additional factors produced by the tumor environment are necessary to promote the survival of primary myeloma cells,
together with IL-6 3 . Searching for such intercellular communication signals with DNA arrays, we found that some myeloma cell lines expressed heparin-binding epidermal growth factor-like growth factor (HB-EGF) gene 4 and that autocrine HB-EGF was involved in the IL-6-induced survival of two myeloma cell lines 5 .
HB-EGF is one of the 11 members of the epidermal growth factor (EGF)-related peptide growth factor family. This family binds to and induces the homo-or heterodimerization of three receptors: the EGF receptor ErbB1, ErbB3, and ErbB4. ErbB2 is a fourth member unable to bind EGF ligands. ErbB2 is a preferred heterodimerization partner for all other ErbB members and increases ErbB receptor signaling 6 . The EGF family includes EGF, transforming growth factor-α, amphiregulin, and epigen, which bind to ErbB1, and HB-EGF, betacellulin, and epiregulin, which bind to both ErbB1 and ErbB4 7 . It also includes the four neuregulins. Neuregulin 1 and 2 bind to both ErbB3 and ErbB4
and neuregulin 3 and 4 only to ErbB4 8 . ErbB receptors can cross-communicate with other receptors, including growth hormone receptor 9 , G-protein-coupled receptors 10 , gp130 IL-6 transducer 11, 12 or IGF-1 receptor 13, 14 . Recently, interferon-α (IFN-α) was shown to trigger ErbB3 phosphorylation in the KAS-6/1 myeloma cell line 15 .
An abnormal expression of ErbB receptors and/or EGF family ligands has been reported in numerous cancers [16] [17] [18] . In particular, ErbB1 is expressed or overexpressed in a wide variety of solid human tumors, including non-small cell lung (NSCL), prostate, breast, colorectal, and ovarian cancers 19 . The ErbB4 gene is also amplified in cancer and is associated with a poor prognosis 20 . The
ErbB2 gene is frequently amplified in epithelial cancers, mainly melanoma, breast, and ovarian cancers, leading to abnormal EGF signaling 21 . Expression of ErbB3 is seen in many of the same tumor types that overexpress ErbB2 22 .
The involvement of the EGF/ErbB family in cancer has encouraged the development of two families of ErbB inhibitors in clinical studies: monoclonal antibodies and ErbB tyrosine kinase inhibitors. ErbB kinase inhibitors are small molecules that compete with adenosine triphosphate binding to the ErbB kinase domains. They block ErbB kinase activity specifically, but not the activity of other receptors 23 . Antibodies to ErbB2 are currently used in the treatment of breast and ovarian cancers. Antibodies to ErbB1 and inhibitors of ErbB kinase activity are under active investigation in phase I-III trials for a variety of tumors 24 .
In this study, we show that HB-EGF was a growth factor for six out of nine myeloma cell lines that expressed ErbB1 and/or ErbB4 HB-EGF receptors, but not for three nonresponsive cell lines. HB-EGF activity required a low concentration of IL-6 and was blocked by an anti-IL-6 antibody. HB-EGF triggered the PI-3K/AKT pathway, but not the JAK/STAT and MAPK pathways. The biological activity of HB-EGF was blocked by PD169540, a pan-ErbB kinase inhibitor analog to the CI-1033 clinical-grade inhibitor 25 . PD169540 ErbB inhibitor induced primary myeloma cells apoptosis in short-term culture and strongly potentiated dexamethasone (DEX) or anti-IL-6 monoclonal antibody (MoAb)-induced apoptosis. Altogether, these data provide a framework for targeting the ErbB pathway in novel, biologically based therapeutics in multiple myeloma.
Materials and Methods

Myeloma cell lines and reagents
The human myeloma cell lines (HMCLs) were obtained in our laboratory and their characteristics have been reported previously 4, 26, 27 . Eight are IL-6-dependent myeloma cell lines (XG-1, XG-2, XG-5, XG-6, XG-7, XG-11, XG-16, XG-19). Their growth is dependent on addition of exogenous IL-6. Upon removal of IL-6, myeloma cells progressively apoptose 3, 28 . One is autonomously growing (RPMI 8226). The
HMCLs were routinely maintained in RPMI 1640, 10% fetal calf serum (FCS) and 2 ng/ml of IL-6. The experiments were performed in RPMI 1640 with 5% FCS.
Bone marrow or peripheral blood samples were obtained from patients with intramedullary myeloma or with plasma cell leukemia (PCL), after they had provided informed consent. Recombinant HB-EGF and IL-6 were purchased from R&D Systems (Minneapolis, MN), the PD153035 and AG1478 ErbB1 inhibitors from Alexis Biochemicals (San Diego, CA), the LY294002 PI-3 kinase inhibitor from Sigma (St Louis, MO), the PD169540 pan-ErbB kinase inhibitor was a generous gift from Pfizer Global Research and Development (Ann Arbor, MI) and the B-E8 anti-IL-6 MoAb from Dr. Wijdenes (Diaclone, Besancon, France).
Cell proliferation assay
Cells were cultured for 5-7 days (depending on the cell lines) in 96-well flat-bottomed microtiter plates at 10 4 cells/well in 200 µl of RPMI 1640 culture medium and 5%
FCS. Various concentrations of cytokines or growth factors or inhibitors of cytokine/growth factor were added at the beginning of the culture in six culture wells per group. At the end of the culture, cells were pulsed with tritiated thymidine (Amersham Pharmacia Biotech, Orsay, France) for 12 hours, then harvested and counted as reported previously 29 .
Detection of apoptotic cells
Myeloma cells were cultured for 3 days in 24-well flat-bottomed microtiter plates at 
Reverse transcriptase-polymerase chain reaction
We generated cDNA with 2 µg of total RNA using the Superscript II reverse transcriptase (Life Technologies) and oligo d(T) [12] [13] [14] [15] [16] [17] [18] 
Western Blot
Myeloma cells were starved overnight in RPMI 1640 culture medium in the presence of 1% BSA, without cytokines. Cells were then stimulated with HB-EGF (5 µg/ml), IGF-1 (1 µg/ml) or IL-6 (20 ng/ml) for 15 min at 37°C. Cells were lysed in 10 mM TrisHCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate (NaPPi), 1%
triton X-100, 5 µM ZnCl 2 , 100 µM Na 3 VO4, 1 mM DTT, 20 mM β-glycerophosphate, 20 mM p-nitrophenolphosphate (PNPP), 20 µg/ml aprotinin, 2.5 µg/ml leupeptin, 0.5 mM PMSF, 0.5 mM benzamidine, 5 µg/ml pepstatin, and 50 nM okadaic acid.
Lysates were resolved in 7.5% sodium dodecyl sulfate-polyacrylamide by gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane 
Mononuclear cells culture
Mononuclear cells from eight patients with MM were cultured for 5 days at 5 × 10 5 cells/ml in RPMI 1640 medium, 5% FCS, 1 ng/ml IL-6, without (control) or with the PD169540 pan-ErbB inhibitor (1 µM), the B-E8 anti-IL-6 MoAb (10 µg/ml) or 10 -6 M Dexamethasone (DEX) used alone or in combination. In each culture group, the viability and cell counts were assayed and myeloma cells were stained with an anti-CD138-PE MoAb (Beckman-Coulter, Marseilles, France).
Assay of hematopoietic colony-forming cells
Bone marrow mononuclear cells from five MM patients were grown in a semi-solid culture medium with hematopoietic cytokines (GF H4434, StemCell Technologies, Vancouver, BC, Canada). Cells were cultured without (control) or with the PD169540 pan-ErbB kinase inhibitor (1 µM), the B-E8 anti-IL-6 MoAb (10 µg/ml) or 10 -6 M DEX used alone or in combination. The number of granulocyte-macrophage colonies was counted on day 14 of incubation.
Statistical analysis
Results were compared with a Student t test or a Wilcoxon test for pairs.
Results
Gene expression of EGF receptor family members and HB-EGF in myeloma cell
lines.
Gene expression of the four members of the EGF receptor family was studied in nine Figure 1B ). In agreement with our previous report 4 , we found HB-EGF expression in two out of nine myeloma cell lines ( Figure 1A ).
Sensitivity of myeloma cell lines to HB-EGF.
To investigate the effect of HB-EGF on myeloma cell growth, we first used the XG-1
and XG-6 cell lines, which cannot survive and proliferate without adding IL-6 when cultured at a low cell density 26 . HB-EGF induced the proliferation of XG-1 cells and had no effect on XG-6 cells ( Figure 2) . One difference between XG-1 and XG-6 cells is a low production of autocrine IL-6 by XG-1 cells 33 . This production of autocrine IL-6
by XG-1 cells is too weak to support the growth of XG-1 cells alone but contributed to the HB-EGF-induced proliferation since it was abrogated by anti-IL-6 MoAb ( Figure   2 ). In the presence of a low IL-6 concentration (5 pg/ml), HB-EGF dramatically increased the IL-6-induced proliferation of XG-1 and XG-6 myeloma cells 14-and 12-fold, respectively. Anti-IL-6 MoAb abrogated this effect (Figure 2 ). With a high IL-6 concentration, HB-EGF increased the proliferation of XG-1 cells threefold and did not increase that of XG-6 cells, which was likely already at its maximum level. A significant effect was found with 100 ng/ml of HB-EGF and a maximum effect with 100-1000 ng/ml, depending on the myeloma cell lines (results not shown). Using annexin-V, we observed that HB-EGF protected myeloma cells from apoptosis antibodies or CRM197 mutated diphtheria toxin ( Figure 6D ) 4, 5 . These data demonstrate again that autocrine HB-EGF produced by some myeloma cell lines contributes to their growth induced by recombinant IL-6. As expected, the ErbB inhibitor blocked HB-EGF-induced AKT phosphorylation in XG-7 cells ( Figure 6E ). Its specificity is shown by its lack of effect on IGF-1-induced Akt phosphorylation ( Figure   6E ). Interestingly, it also inhibited IL-6-induced-AKT phosphorylation. This observation is in agreement with the inhibition of IL-6-dependent proliferation of this HB-EGF-producing cell line by ErbB inhibitor ( Figure 6D ) and indicates a cooperation between gp130 and ErbB transduction pathways.
We then tested other two inhibitors known to block ErbB1 tyrosine kinase activation, AG1478 and PD153035, on the three ErbB1-positive myeloma cell lines, XG-5, XG-7
and XG-11. These two inhibitors also blocked the HB-EGF-induced proliferation of the three ErbB1 myeloma cell lines in a manner similar to PD169540 ( Figure 7) . As all myeloma cell lines express the ErbB2 gene and as ErbB2 can participate in the HB-EGF-induced signaling 36 , we also tested the Herceptin anti-ErB2 antibody 37 . We found that this antibody did not affect HB-EGF-induced myeloma cell proliferation (results not shown).
The pan ErbB kinase inhibitor potentiates dexamethasone-induced or anti-IL-6
MoAb-induced apoptosis of patient myeloma cells.
We first looked for the expression of ErbB receptors in primary purified myeloma cells from five patients with intramedullary myeloma and four patients with plasma cell leukemia. As indicated in Figure 8A , seven out of nine purified primary myeloma cells figure 9A ). The effect of DEX was less marked and not significant (P=.07). Of major interest, the pan-ErbB inhibitor dramatically increased both anti-IL-6 MoAb-induced or DEX-induced apoptosis. We observed a 76%
reduction of the number of viable myeloma cells with anti-IL-6 MoAb and the ErbB inhibitor (P=.0028) and a 84% reduction with DEX and the ErbB inhibitor (P=.0028) ( Figure 9A ). In two patients, the three compounds had no effect on myeloma cell survival, either used alone or in combination (Table 1) . Interestingly, the pan ErbB inhibitor had no effect on the survival of other bone marrow non myeloma cells ( Figure 9B ). We then looked for the effect of the pan-ErbB kinase inhibitor on the growth of hematopoietic precursors present in the bone marrow of five MM patients using a methylcellulose semi-solid assay ( Figure 10A ). None of the three, pan-ErbB kinase inhibitor, DEX or anti-IL-6 MoAb, significantly affected it, either used alone or in combination (P>.5).
Effect of HB-EGF inhibitor on the adhesion of myeloma cells to BMSCs and IL-6
production.
As HB-EGF is expressed by MM patients' stromal cells and can be involved in juxtacrine intercellular communication 38 , we investigated whether the PD169540 could affect the adhesion of myeloma cell to BMSCs. About 20% myeloma cells adhered to BMSCs and pretreatment of both myeloma cells and BMSCs with the pan-ErbB inhibitor did not affect myeloma cell adhesion to stromal cells ( Figure 10B ).
Given that binding of myeloma cells to BMSCs had been proven important to
promote IL-6 production by stromal cells and myeloma cell survival 31,39 , we next investigated whether the PD169540 could affect the secretion of IL-6 by BMSCs cocultured with myeloma cells. IL-6 secretion was 889±17 pg/ml without ErbB inhibitor and 810±43 pg/ml with ErbB inhibitor. No IL-6 was detected in the supernatant of myeloma cells (results not shown). Therefore the pan-ErbB inhibitor did not significantly affect the IL-6 production by stromal cells cultured with myeloma cells.
Discussion
As we initially found that the HB-EGF gene was expressed in some myeloma cell lines and could stimulate their growth 4,5 , our aim was to investigate whether this observation was a common feature in multiple myeloma and whether ErbB inhibitors could be potentially useful in treating this disease.
Firstly, we show here that HB-EGF expression is not a salient feature of primary myeloma cells. There is no HB-EGF gene expression in the purified myeloma cells of eight out of nine MM patients. HB-EGF expression was found in the myeloma cells of only one patient with plasma cell leukemia. An autocrine production of HB-EGF by myeloma cells could eventually make it possible to obtain a myeloma cell line in vitro, explaining why two myeloma cell lines out of nine express the HB-EGF gene.
Interestingly, the bone marrow tumor environment of all eight MM patients expressed the HB-EGF gene. Monocytes were purified from three patients with MM and were found to express the HB-EGF gene. This was expected because stimulated monocytes are known to produce HB-EGF 40 and monocytes are highly activated in MM patients' bone marrow, in particular producing high levels of IL-6 41 . HB-EGF expression was also found in the five stromal cell lines derived from the bone marrow of patients with MM. We could not directly assay for a production of HB-EGF protein because a sensitive HB-EGF ELISA is not commercially available. Thus, these current data emphasize that the bone marrow environment of patients with MM produces HB-EGF, in particular monocytes and stromal cells and that primary myeloma cells rarely express the HB-EGF gene.
Secondly, we found that myeloma cells from six out of nine myeloma cell lines and myeloma cells from nine out of nine patients expressed the two HB-EGF receptor genes, ErbB1 and/or ErbB4. Using RT-PCR, we did not detect ErbB expression in polyclonal plasmablasts generated from normal peripheral blood B cells using the methodology we recently reported 42 . In agreement with this study, we found that an
ErbB inhibitor did not affect the generation of plasmablasts (results not shown).
These results are intriguing and suggest that ErbB is either expressed on bone marrow plasmocytes, unlike plasmablasts, or involved in plasma cell oncogenesis.
We are now trying to obtain purified bone marrow plasma cells to investigate this point, but these cells are rare cells (0.25% of bone marrow cells) and for ethical reasons, it is difficult to obtain enough normal bone marrow to purify them. MoAb. As ErbB2 participated in HB-EGF response in various cells 36 , this suggests that ErbB2 expression in myeloma cells is too weak to be functional. The PD169540
pan ErbB inhibitor did not affect the IL-6-induced proliferation of the XG-6 myeloma cells that did not express the HB-EGF gene. It had no toxicity on the 14-day growth of bone marrow hematopoietic progenitors. As HB-EGF is a membrane protein that can be involved in juxtacrine stimulation and is produced by bone marrow stromal cells, we looked for a putative role of PD169540 on the interaction of myeloma cells and BMSCs in accordance with the model reported by Uchimaya et al 31 . We found that the ErbB inhibitor had no effect on myeloma cell adhesion to stromal cells or on IL-6 production by stromal cells cocultured with myeloma cells.
It is of major interest that the pan-ErbB kinase inhibitor induced a 55% reduction in the number of viable primary myeloma cells cultured for several days together with their bone marrow environment, which expresses the HB-EGF gene. In association with DEX, it induced an 84% reduction in myeloma cell number, whereas DEX alone induced only a 36% reduction. A similar additive effect was observed with an anti-IL-6
MoAb. Interestingly, this toxicity was specific to myeloma cells and no reduction in the number of non-myeloma cells was observed. Several ErbB inhibitors are in various stages of clinical development and some are producing significant clinical responses. The compound that is at the most advanced stage of development is IRESSA (ZD1839), which targets EGFR. This compound has shown an acceptable tolerability and promising clinical efficacy in phase I trials and is currently in phase III trials in advanced NSCL and breast cancers 49 . CI-1033 is another clinical-grade irreversible tyrosine kinase inhibitor that is unique because it targets the three ErbB members with kinase activity 25 . It has potent and long-lasting in vivo activity in a range of tumor models. For example, it has demonstrated antitumor activity against A431 and H125 tumors in vivo 50 . Data from three phase I trials in patients with head and neck, breast and NSCL cancers showed that CI-1033 is generally well tolerated 51 . A phase II study in patients with advanced ovarian cancer and a randomized phase II trial with patients with NSCL after a first or second line of chemotherapy are being done 52 .
In conclusion, our data are very encouraging and provide a framework for clinical evaluation of ErbB inhibitors in patients with MM, alone and coupled with dexamethasone or anti-IL-6 MoAb, now available for clinical use 53 . A first step will be to investigate in preclinical studies whether ErbB inhibitors can block the growth of myeloma cell lines and primary myeloma cells with SCID mice models of human multiple myeloma 27, 54 . These current data are in agreement with the recent development of novel biologically based treatment approaches that target mechanisms whereby MM cells grow and survive in their bone marrow environment.
The most relevant example is the proteasome inhibitor PS341, which was identified as a promising new therapeutic agent in multiple myeloma 55 . Table 1 . Effect of the pan-ErbB inhibitor on the survival of primary myeloma cells.
Myeloma cell count/ml. XG-1 and XG-6 cells were IL-6-starved for 3 hours and cultured in RPMI1640 culture medium and 5% FCS with either 5 pg/ml IL-6, or 5 pg/ml IL-6 and 1 µg/ml HB-EGF, or 500 pg/ml IL-6, or 500 pg/ml IL-6 and 1 µg/ml HB-EGF (with or without 10 µg/ml B-E8 anti-IL-6 MoAb). Cells were cultured for 6 days and were pulsed for 12 hours with tritiated thymidine at the end of the culture. Data are means ± SD of the tritiated thymidine incorporation determined on sixplicate culture wells and are those of one experiment representative of four. XG-1 cells were IL-6 starved for 3 hours and cultured in RPMI 1640 culture medium and 5% FCS with either 5 pg/ml IL-6, or 5 pg/ml IL-6 and 1 µg/ml HB-EGF, or 500 pg/ml IL-6, or 500 pg/ml IL-6 and 1 µg/ml HB-EGF (with or without 10 µg/ml B-E8
anti IL-6 MoAb). Cells were cultured for 3 days and stained with FITC-annexin V to Amplification of β-actin shows the equivalence of the cDNA loading and amplification.
Results are of one experiment representative of three. anti-IL-6 MoAb (B-E8, 10 µg/ml) or dexamethasone (DEX, 10 -6 M), alone or in combination, for 5 days. As endogenous production of IL-6 is highly variable in shortterm culture of patients' bone marrow, 1 ng/ml recombinant IL-6 was added to eliminate this source of variability. In each culture group, viability and cell counts were assayed and myeloma cells were stained with an anti-CD138-PE antibody.
Results are median values of the numbers of myeloma (A) or non-myeloma cells (B), compared to that of the control group, which assigned the value of 100%. Only the six responder patients listed in Table 1 are represented there.
* Indicates a statistically significant difference of the median value compared to that of the control group using a Wilcoxon test for pairs (P≤.05).
**Indicates a statistically significant difference of the median value compared to that obtained with the anti-IL-6 MoAb or the DEX groups using a Wilcoxon test for pairs (P≤.05). 
